Loading
HKSEHealthcareBiotechnology
Latest quote
HK$0.875
−HK$0.005 · -0.57%
Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.
Latest quote
HK$0.875
−HK$0.005 · -0.57%
Regular session · HKT · Market data may be delayed.
Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.
Day range
Current HK$0.875
52-week range
Current HK$0.875
Regular session · HKT · Market data may be delayed.
Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.
Day range
Current HK$0.875
52-week range
Current HK$0.875
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 18.12M CNY | 54.29M CNY | 56.32M CNY | 51.63M CNY | 92.54M CNY |
| Gross profit | — | 54.29M CNY | 56.32M CNY | 51.63M CNY | 92.54M CNY |
| Research and development | 206.74M CNY | 249.85M CNY | 402.71M CNY | 440.63M CNY | 494.62M CNY |
| Selling, general, and administrative | 101.67M CNY | 203.94M CNY | 57.1M CNY | 80.33M CNY | 79.31M CNY |
| Operating expenses | 310.26M CNY | 453.79M CNY | 600.62M CNY | 565.81M CNY | 703.02M CNY |
| Interest income | 50.2M CNY | 84.79M CNY | 108.02M CNY | 37.2M CNY | 6.49M CNY |
| Interest expense | 1.91M CNY | — | 494K CNY | 851K CNY | 1.18M CNY |
| Depreciation and amortization | 5.59M CNY | 6.99M CNY | 15.67M CNY | 7.94M CNY | 7.68M CNY |
| Operating income | −295.88M CNY | −399.5M CNY | −544.3M CNY | −513.85M CNY | −610.48M CNY |
| Net income | −216.86M CNY | −508.16M CNY | −174.83M CNY | −484.31M CNY | −4.12B CNY |
Company facts updated Sep 15, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Emerging Markets Small Cap ETFEWX
Avantis Emerging Markets Equity ETFAVEM
Avantis Responsible Emerging Markets Equity ETFAVSEAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
